oncology
GI Cancer

KEYNOTE-177 supports pembrolizumab in MSI-high colorectal cancer

Pembrolizumab has been shown to significantly benefit patients with MSI-high/dMMR metastatic colorectal cancer. In a presentation to the 2020 ASCO Virtual Scientific Program, Professor Thierry Andre from the Sorbonne University said the checkpoint inhibitor should now be the standard of care in first line therapy. The KEYNOTE-177 study compared outcomes in 307 patients from 23 ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic